Analyst Price Targets — BBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 10:03 am | — | H.C. Wainwright | $120.00 | $85.89 | TheFly | BridgeBio price target raised to $120 from $110 at H.C. Wainwright |
| June 16, 2026 10:40 am | Salim Syed | Mizuho Securities | $96.00 | $68.00 | StreetInsider | BridgeBio Pharma (BBIO) PT Lowered to $96 at Mizuho |
| June 3, 2026 10:00 am | — | Canaccord Genuity | $104.00 | $63.88 | TheFly | BridgeBio initiated with a Buy at Canaccord |
| May 28, 2026 12:27 pm | — | Morgan Stanley | $98.00 | $65.59 | TheFly | BridgeBio price target raised to $98 from $94 at Morgan Stanley |
| May 11, 2026 10:03 am | — | H.C. Wainwright | $110.00 | $67.39 | TheFly | BridgeBio price target raised to $110 from $100 at H.C. Wainwright |
| May 8, 2026 11:57 am | — | Evercore ISI | $130.00 | $66.53 | TheFly | BridgeBio price target raised to $130 from $125 at Evercore ISI |
| May 8, 2026 11:55 am | — | Bernstein | $114.00 | $67.45 | TheFly | BridgeBio price target raised to $114 from $100 at Bernstein |
| April 29, 2026 12:46 pm | Danielle Brill | Truist Financial | $102.00 | $70.08 | TheFly | BridgeBio price target raised to $102 from $95 at Truist |
| April 8, 2026 8:20 pm | Luca Issi | RBC Capital | $100.00 | $74.14 | TheFly | BridgeBio initiated with an Outperform at RBC Capital |
| March 12, 2026 1:24 pm | Mani Foroohar | Leerink Partners | $98.00 | $68.77 | StreetInsider | Leerink Partners Reiterates Outperform Rating on BridgeBio Pharma (BBIO) after data presentation: "risk/reward skewed to the upside" |
Latest News for BBIO
Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 10.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 889,356 shares of the company's stock after selling 104,864 shares during the quarter. Allspring Global Investments Holdings
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia…
PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 37 new employees in restricted stock units for an aggregate of 83,283 shares of the…
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBIO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.